Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2
Full-year 2026 guidance reaffirmed o Net sales expected to grow low single-digit and core operating income expected to decline low single-digit
Novartis says its overall sales will grow just a tiny bit in 2026, but some of its newer medicines like Kisqali are selling really well with much bigger growth. When a company's new drugs do great while the whole business grows slowly, it hints the company might be shifting to focus on newer, stronger products.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.